RQ Bio Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 14

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $115M

  • Investors
  • 9

RQ Bio General Information

Description

Operator of a biotechnology company intended to develop medicines based on potent, broad-spectrum mAbs to provide instant and long-lasting protection for vulnerable people. The company provides medicines to prevent diseases like polio, rabies, measles, tetanus, hepatitis, mumps, and dengue, enabling pharmaceutical companies to develop antibodies to protect against infectious diseases where vaccines cannot.

Contact Information

Website
www.rqbiotechnology.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Scale Space
  • 58 Wood Lane
  • London W12 7RZ
  • England, United Kingdom
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
LOHAS & Wellness, HealthTech, Life Sciences
Corporate Office
  • Scale Space
  • 58 Wood Lane
  • London W12 7RZ
  • England, United Kingdom

RQ Bio Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

RQ Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series A) 04-Jun-2026 $115M Completed Generating Revenue
2. Early Stage VC 02-Dec-2022 Completed Generating Revenue
1. University Spin-Out 26-Mar-2021 Completed Stealth
To view RQ Bio’s complete valuation and funding history, request access »

RQ Bio Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Ordinary
To view RQ Bio’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

RQ Bio Patents

  • 25

    Total Documents Applications and Grants

  • Total Patents Families

  • 3

    Granted

  • 7

    Pending

  • Expiring in next 12 mo

RQ Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202203423-D0 Antibodies Inactive 11-Mar-2022
GB-202202232-D0 Antibodies Inactive 18-Feb-2022
GB-202305426-D0 Antibodies Active 18-Feb-2022
GB-2614651-A Antibodies Active 18-Feb-2022
GB-2614651-B Antibodies Active 18-Feb-2022 C07K16/10
To view RQ Bio’s complete patent history, request access »

RQ Bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

RQ Bio Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
EQT Life Sciences Venture Capital Minority
Forbion Venture Capital Minority
Frazier Healthcare Partners PE/Buyout Minority
Monograph Capital Venture Capital Minority
Oxford Science Enterprises Venture Capital Minority
You’re viewing 5 of 9 investors. Get the full list »

Ready to get started?

Request a free trial

RQ Bio FAQs

  • When was RQ Bio founded?

    RQ Bio was founded in 2021.

  • Where is RQ Bio headquartered?

    RQ Bio is headquartered in London, United Kingdom.

  • What is the size of RQ Bio?

    RQ Bio has 14 total employees.

  • What industry is RQ Bio in?

    RQ Bio’s primary industry is Biotechnology.

  • Is RQ Bio a private or public company?

    RQ Bio is a Private company.

  • What is RQ Bio’s current revenue?

    The current revenue for RQ Bio is .

  • How much funding has RQ Bio raised over time?

    RQ Bio has raised $117M.

  • Who are RQ Bio’s investors?

    EQT Life Sciences, Forbion, Frazier Healthcare Partners, Monograph Capital, and Oxford Science Enterprises are 5 of 9 investors who have invested in RQ Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process